ISSN:
1573-8280
Keywords:
autotransplantation
;
CD34
;
granulocyte colony-stimulating factor
;
peripheral blood stem cell
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract The number of circulating progenitor cells increases during the period of hematopoietic recovery following myeloablative therapy. These progenitor cells were used for autologous transplantation in order to reconstitute hematopoiesis. As an indicator of the circulating progenitor cells, the number of granulocyte-macrophage colony forming units (CFU-GM), which is measured by means of a long-term cell culture, has been widely used. Recently, a cell surface marker, CD34, which can easily be measured by means of flowcytometry, was found to represent immature hematopoietic progenitor cells, which are very close to stem cells. Therefore, the relationship between the number of CD34 positive cells (CD34+ cells) and the number of CFU-GM in the peripheral blood following chemotherapy was studied in 9 patients selected to undergo autotransplantation. The number of peripheral blood CD34+ cells was found to be significantly correlated with that of CFU-GM (r = 0.81). When four out of 9 patients received recombinant human granulocyte-colony stimulating factor (rG-CSF) administration, a significant increase in the release of peripheral blood CD34+ cells as well as peripheral blood CFU-GM was observed (P〈0.01). Thus, the measurement of CD34+ cells is useful for predicting the number of circulating CFU-GM.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF02171698
Permalink
